Briles D E, Hollingshead S, Brooks-Walter A, Nabors G S, Ferguson L, Schilling M, Gravenstein S, Braun P, King J, Swift A
Department of Microbiology, University of Alabama at Birmingham, 658 BBLB, 845 19th Street South, Birmingham, AL 35294, USA.
Vaccine. 2000 Feb 25;18(16):1707-11. doi: 10.1016/s0264-410x(99)00511-3.
Pneumococcal proteins, alone, in combination with each other, or in combination with capsular polysaccharide-protein conjugates may be useful pneumococcal vaccine components. Four proteins with a potential for use in vaccines are PspA, pneumolysin, PsaA, and PspC. In a mouse model of carriage, PsaA and PspC were the most efficacious vaccine proteins. Of these, PsaA was the best at eliciting protection against carriage. However, a combination of PspA and pneumolysin may elicit stronger immunity to pulmonary infection and possibly sepsis than either protein alone. Recently, a phase one trial of a recombinant family 1 PspA was completed in man. PspA was observed to be safe and immunogenic. Injection of 0.1 ml of immune serum diluted to 1/400 was able to protect mice from fatal infection with S. pneumoniae. Under these conditions, pre-immune serum was not protective. The immune human serum protected mice from infections with pneumococci expressing either of the major PspA families (1 and 2) and both of the pneumococcal capsular types tested: 3 and 6.
肺炎球菌蛋白单独使用、相互组合或与荚膜多糖 - 蛋白结合物组合，都可能是有用的肺炎球菌疫苗成分。四种有潜力用于疫苗的蛋白是肺炎球菌表面蛋白A（PspA）、肺炎溶血素、肺炎球菌表面黏附素A（PsaA）和肺炎球菌表面蛋白C（PspC）。在携带模型小鼠中，PsaA和PspC是最有效的疫苗蛋白。其中，PsaA在引发针对携带状态的保护方面效果最佳。然而，PspA和肺炎溶血素的组合可能比单独使用任何一种蛋白都能引发更强的针对肺部感染以及可能的败血症的免疫力。最近，重组1型PspA在人体中完成了一期试验。观察到PspA是安全且具有免疫原性的。注射0.1毫升稀释至1/400的免疫血清能够保护小鼠免受肺炎链球菌的致命感染。在这些条件下，免疫前血清没有保护作用。免疫后的人血清保护小鼠免受表达两种主要PspA家族（1型和2型）以及两种测试的肺炎球菌荚膜类型（3型和6型）的肺炎球菌感染。
